FibroScan®
Clinical e-news
The newsletter designed to keep the FibroScan® community up-to-date on clinical news and resources.
The following articles are the latest clinical peer-reviewed publications on liver health management.
In this European multicenter study of patients with cACLD, predominantly due to metabolic diseases, SSM by VCTE™ at 100 Hz significantly improved non-invasive diagnosis of CSPH compared to standard methods. The comprehensive model (NICER) incorporating SSM, LSM, platelet count, and BMI establishes a new standard for CSPH risk stratification, enhancing access to disease-modifying treatments for these patients.
The FIB-4 score / VCTE™ algorithm showed excellent diagnostic performance, demonstrating its applicability for routine screening in diabetology.
- Effective Screening: A two-step strategy (FIB-4 score followed by VCTE™) effectively identifies patients at high risk of advanced fibrosis.
- Noninvasive Test Performance: FIB-4 outperformed NFS and MAF-5, with a high negative predictive value (97.2%) for ruling out advanced fibrosis.
- Referral to Specialized Care: The FIB-4/VCTE™ strategy led to appropriate referrals for hepatology care, though 2% of referrals were false positives.
- Practical for Clinics: The two-step approach is practical and effective for identifying high-risk patients in diabetology and nutrition clinics.
This cross-sectional study from Sweden demonstrated that screening for liver fibrosis using VCTE™ during routine retina scans in people with type 2 diabetes is highly accepted and feasible, with over half showing metabolic dysfunction-associated steatotic liver disease and 7.4% confirmed with significant fibrosis.